PLCB3 and myeloproliferative disorder: In hematopoietic stem cells (HSCs), loss of PLCβ3 led to STAT5 hyperactivation, thereby increasing the number of HSCs with a myeloid differentiation ability and leading to the development of myeloproliferative neoplasms in PLCβ3-KO mice [98].